It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
The review found no eligible studies for this question.
PIMOZIDE showed no clear difference in global state: relapse medium term (3‐12 months) Clinical diagnoses compared with ANY ANTIPSYCHOTIC (moderate certainty).
It is very uncertain whether PIMOZIDE changes mental state: no improvement medium term (3‐12 months) As defined in… compared with ANY ANTIPSYCHOTIC (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes global state: 1. No clinically significant response in global state… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes mental state/behaviour: clinically significant agitation (2‐10 weeks) compared with OTHER DOSES (very low certainty).
HALOPERIDOL probably leads to lower overall improvement: No marked global improvement Rated by clinician compared with PLACEBO (moderate certainty).
It is very uncertain whether HALOPERIDOL changes not discharged from hospital compared with PLACEBO (very low certainty).
It is very uncertain whether HALOPERIDOL changes relapse compared with PLACEBO (very low certainty).
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
HALOPERIDOL probably leads to higher adverse effects: Movement disorders ‐ parkinsonism compared with PLACEBO (moderate certainty).
It is very uncertain whether early warning signs training and treatment as usual changes relapse: Rate of relapse compared with treatment (very low certainty).
It is very uncertain whether early warning signs training and treatment as usual changes relapse: Time to relapse compared with treatment (very low certainty).